PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax Files $100 Million Shelf Registration Statement

MALVERN, Pa., Dec. 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission. When declared effective, the registration statement will allow the company to issue securities, which may consist of common stock, preferred stock, warrants, or any combination thereof, in one or more future offerings up to a maximum aggregate offering price of $100 million.

Commenting on this new shelf registration statement, Gary C. Evans, Chairman of the Board, stated, "While Novavax currently has no current plans to access either the public or private equity markets, we believe it is prudent to be prepared for any future financial requirements that may be necessary as we continue to execute our business plan."

The registration statement on Form S-3 has not yet become effective, and the securities may not be offered or sold until such time as the registration statement is declared effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy such securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under applicable law. A prospectus supplement will describe the terms of any particular offering made under the universal shelf registration statement.

About Novavax, Inc.

Novavax, Inc. is a product development company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) (paucillamellar non-phospholipid liposomes) and Sterisomes(R) (subcutaneous depot injection). Novavax's vaccine technologies include its virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies.

Forward-Looking Statements

Statements made in this press release that state Novavax's or its management's intentions, hopes, beliefs, expectations, or predictions are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners; competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10-K for the year ended December 31, 2004 and quarterly reports on Form 10-Q for the quarters ended March 31, 2005, June 30, 2005 and September 30, 2005, incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355, Tel 484-913-1200 or the SEC at http://www.sec.gov.

CONTACT:
Kathy Hamilton, Investor Relations
(484) 913-1213
KHamilton@novavax.com

SOURCE Novavax, Inc.

CONTACT: Kathy Hamilton, Investor Relations, Novavax, +1-484-913-1213,
KHamilton@novavax.com